Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $9 | $9 | $8 |
| - Cash | $1 | $0 | $1 | $1 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | – | $9 | $9 | $8 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 35.2% | 56.6% | -42% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 89.5% | 80.1% | 82.6% | 91.9% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -25% | 1.5% | -43.8% | -21.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -28.5% | -24.6% | -93.7% | -22.1% |
| EPS Diluted | -1 | -0.82 | -1.58 | -0.64 |
| % Growth | -22% | 48.1% | -146.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |